Allyx Therapeutics

https://www.allyxthera.com/

Background

Allyx Therapeutics is a clinical-stage biotechnology company based in New Haven, Connecticut, developing novel therapies for Alzheimer’s disease and other neurodegenerative diseases. Its approach focuses on protecting synapses, the connections between neurons that support memory and cognitive function. The company’s lead candidate, ALX-001, is an oral small molecule designed to block harmful signaling associated with synapse loss while preserving normal glutamate signaling.